JTB

Across TCGA pan-cancer cohorts, JTB mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated JTB data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher JTB mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated JTB expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

HNSC, CCRCC, and UCEC are the cancer types where JTB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.873	0.687	.001	37	view →
CCRCC	DFS	Tertile	III,IV	0.258	0.718	.004	32	view →
UCEC	OS	Tertile	All	1.000	0.894	.026	4	view →
LUAD	OS	Quartile	All	0.854	0.636	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

JTB–HNSC (DFS)

Open the HNSC breakdown →